there is no assurance that it will be able to effectively target these other two ocular disorder types. Aura Biosciences has been able to achieve two key milestones in the past year. The first ...
Research and development expenses increased to $17.0 million for the three months ended September 30, 2024 from $15.4 million for the three months ended September 30, 2023 primarily due to ...